ImmunoEdge

Cover Block

PUBLIC

Attribute	Value
Name	ImmunoEdge
Tagline	Unlocking immune targets from minimal tumor samples for precision immunotherapy in various diseases.
Headquarters	Heidelberg, Germany
Founded	2023
Stage	Pre-Seed
Business Model	B2B
Industry	Deeptech
Technology	Biotech / Life Sciences
Geography	Western Europe
Growth Profile	Venture Scale
Founding Team	Unknown
Funding Label	Unknown

Links

PUBLIC

• Website: https://www.immunoedge.de
• LinkedIn: https://www.linkedin.com/company/immunoedge

Executive Summary

PUBLIC

ImmunoEdge is a Heidelberg-based biotech startup developing a high-sensitivity, low-loss technology to uncover clinically relevant tumor peptides from minimally invasive biopsies, a critical bottleneck for next-generation immunotherapies [BioRN, Q1 2026]. Founded in 2023, the company's public emergence came with its admission to the BioRN life-science cluster in early 2026, where it was described as supporting actionable target discovery and longitudinal monitoring throughout treatment [BioRN, Q1 2026]. Its core technical claim addresses a known industry problem: current immunopeptidomics workflows can lose up to 99% of tumor immunopeptides from the small biopsy samples that are the clinical reality for many patients [ImmunoEdge, retrieved 2026]. By aiming to extract deeper molecular insights from ultra-low-input material, the platform seeks to enable higher-confidence discovery of immune-visible targets, particularly those missed by genome-based prediction methods [ImmunoEdge, retrieved 2026].

The founding team and any external funding have not been publicly disclosed, placing the company in a very early, pre-seed stage. The business model is presumed B2B, targeting biopharma and biotech companies developing cancer immunotherapies as potential partners or customers. Over the next 12-18 months, key signals to watch will be the disclosure of technical validation data, the naming of founders and initial investors, and the announcement of any research collaborations or pilot programs with established oncology players.

Data Accuracy: YELLOW -- Core product claims are sourced from the company's own materials and a cluster announcement; team and funding details are absent from public records.

Taxonomy Snapshot

Axis	Classification
Stage	Pre-Seed
Business Model	B2B
Industry / Vertical	Biotech / Life Sciences
Technology Type	Deeptech
Geography	Western Europe (Heidelberg, Germany)
Growth Profile	Venture Scale

Company Overview

PUBLIC

ImmunoEdge first appears in the public record in the first quarter of 2026, listed as a new member of the BioRN life-science cluster in Germany's Rhine-Neckar region [BioRN, Q1 2026]. The company describes itself as a Heidelberg-based biotech startup founded in 2023, though no specific founding date or founding story has been disclosed in any primary source. The company's primary public presence is a LinkedIn page, which lists its industry as biotechnology [LinkedIn].

A discrepancy exists regarding its headquarters. While the BioRN membership announcement explicitly lists Heidelberg, Germany, the company's LinkedIn page lists Redwood City, California [BioRN, Q1 2026] [LinkedIn]. This conflict, coupled with the existence of a similarly named US entity, creates a basic identity question that investors should resolve. No information on legal entity structure, such as a German GmbH registration, is available from public filings.

The company's sole verifiable milestone is its admission to the BioRN cluster in Q1 2026, which served as its first public announcement and provided the initial description of its technological focus [BioRN, Q1 2026]. No prior funding announcements, product launches, or named partnerships have been documented in indexed sources.

Data Accuracy: YELLOW -- Key company descriptors (location, founding year) are sourced from a single cluster announcement and an unverified LinkedIn page, with a material conflict on headquarters location.

Product and Technology

MIXED ImmunoEdge is building a platform for immunopeptidomics, the study of peptides presented on the cell surface by immune molecules. The company's core claim is a method that recovers more clinically relevant tumor peptides from far smaller tissue samples than standard workflows allow [BioRN, Q1 2026]. This is framed as a direct response to a known bottleneck: current affinity-based workflows can lose up to 99% of potential immunopeptides when working with the low-input tumor material typical of minimally invasive biopsies [ImmunoEdge, retrieved 2026]. The technology is designed to reduce this loss and bias, aiming to make longitudinal monitoring of a patient's tumor antigen landscape throughout treatment a practical reality [ImmunoEdge, retrieved 2026].

A key differentiator, as presented, is sensitivity at low input. The company states its platform can uncover immune-visible tumor peptides from ultra-low-input biopsies that standard methods miss, unlocking insights for rare and low-input cell populations [ImmunoEdge, retrieved 2026]. The intended output is a higher-confidence set of potential immunotherapy targets, or neoepitopes, moving beyond genome-based predictions that often overlook low-expression but immune-visible peptides [ImmunoEdge, retrieved 2026]. The product surface is described as supporting actionable target discovery and longitudinal monitoring for next-generation immunotherapies like personalized cancer vaccines and T-cell therapies [BioRN, Q1 2026].

Public details on the specific biochemical or engineering techniques are absent. The company's website and BioRN profile emphasize the problem and the desired outcome,higher-fidelity peptide discovery from small samples,over the proprietary mechanism. No technical specifications, performance benchmarks against established methods, or details of a commercial product format (e.g., instrument, reagent kit, software, service) have been disclosed. The technology is presented as being "designed for clinical reality," suggesting a focus on eventual regulatory and clinical workflow integration [ImmunoEdge, retrieved 2026].

Data Accuracy: YELLOW -- Core claims are sourced from the company's own materials and a cluster announcement; no independent technical validation or customer case studies are available.

Market Research

PUBLIC The market for technologies that can translate small, real-world tumor biopsies into actionable immunotherapy targets is defined by a fundamental mismatch between clinical sample availability and the technical requirements of existing discovery platforms.

Third-party sizing for the specific niche of high-sensitivity immunopeptidomics is not publicly available. The broader context is the global personalized cancer vaccine market, which one analysis valued at $2.3 billion in 2024 and projects to reach $7.8 billion by 2030, growing at a compound annual rate of 22.5% [Precedence Research, 2024]. This analogous market reflects the downstream therapeutic applications ImmunoEdge aims to enable. The total addressable market for tools and services supporting neoantigen discovery, a critical upstream step for these vaccines, is logically a subset of this figure, though specific segmentation is not cited in available sources.

Demand is driven by several converging clinical and commercial trends. The shift towards less invasive, serial biopsies for treatment monitoring creates a need for workflows that can operate on minimal material [ImmunoEdge, retrieved 2026]. Simultaneously, the clinical validation of mRNA-based personalized cancer vaccines has intensified the search for reliable, tumor-specific peptide targets, moving the field beyond genome-based prediction alone [BioRN, Q1 2026]. A third driver is the expansion of cell therapies into solid tumors, which requires the identification of safe and effective targets from often heterogeneous and scarce tissue samples.

Adjacent and substitute markets include the broader liquid biopsy segment, which analyzes circulating tumor DNA (ctDNA) for genomic alterations, and traditional proteomics services offered by large instrument companies. The key differentiator for an immunopeptidomics platform is its focus on the peptides actually presented by the tumor's HLA molecules, which are the direct targets for T-cells, rather than inferred targets from DNA or RNA sequencing.

Regulatory and macro forces are generally favorable but introduce complexity. Regulatory agencies are increasingly familiar with biomarker and companion diagnostic development for targeted therapies, potentially smoothing a path for clinical assay validation. However, the macro environment for early-stage biotech funding in Europe has become more selective, placing a premium on capital efficiency and clear, de-risked technical milestones.

Personalized Cancer Vaccines 2024 | 2.3 | $B
Personalized Cancer Vaccines 2030 | 7.8 | $B

The projected growth of the personalized cancer vaccine market, while an indirect proxy, underscores the commercial potential for enabling technologies that improve target discovery. The 22.5% CAGR suggests a receptive and expanding endpoint market for ImmunoEdge's proposed tools.

Data Accuracy: YELLOW -- Market sizing is drawn from a single third-party report for an analogous, downstream market. Specific TAM/SAM for the immunopeptidomics tools segment is not confirmed.

Competitive Landscape

MIXED ImmunoEdge enters a competitive field defined by large-scale platform companies and specialized biotech players, all aiming to improve the identification of tumor antigens for immunotherapy.

Company	Positioning	Stage / Funding	Notable Differentiator	Source
ImmunoEdge	High-sensitivity, low-loss tumor peptide discovery from minimal biopsies for immunotherapy target ID and monitoring.	Pre-Seed (estimated). No public funding.	Focus on ultra-low-input clinical samples and longitudinal monitoring from small biopsies.	[BioRN, Q1 2026]
Immatics	Clinical-stage biotech developing TCR-based immunotherapies and XPRESIDENT® target discovery platform.	Public (Nasdaq: IMTX). Over $1B market cap.	Integrated pipeline from proprietary target discovery to clinical-stage T-cell therapies.	[Immatics, 2024]
NantWorks	Holding company with subsidiaries (e.g., NantHealth, ImmunityBio) in AI-driven healthcare and immunotherapy.	Private. Multi-billion dollar portfolio.	Broad ecosystem integrating diagnostics, data analytics, and therapeutic development.	[NantWorks, 2024]
Illumina	Global leader in DNA sequencing and array-based technologies for genomic analysis.	Public (Nasdaq: ILMN). ~$20B market cap.	Dominant market share in sequencing hardware and consumables for genomic research.	[Illumina, 2024]
Waters	Analytical instrument manufacturer for liquid chromatography, mass spectrometry, and bioanalytical workflows.	Public (NYSE: WAT). ~$20B market cap.	Provider of core instrumentation for proteomics and metabolomics research labs.	[Waters, 2024]

The competitive map breaks into three distinct layers. The first layer consists of integrated biotech platforms like Immatics, which combine proprietary target discovery with an internal therapeutic pipeline. These companies are direct competitors for the end goal of developing immunotherapies, but they also represent potential licensing partners or customers for a superior discovery tool. The second layer includes enabling technology giants such as Illumina and Waters. They provide the foundational instruments (sequencers, mass spectrometers) used in standard immunopeptidomics workflows. ImmunoEdge’s technology, if successful, would aim to be a superior sample preparation and analysis layer that sits on top of these established hardware platforms, rather than displacing them. The third layer comprises adjacent substitutes, including computational prediction platforms that infer neoepitopes from genomic data alone, a method ImmunoEdge’s literature directly critiques for missing low-expression, immune-visible peptides [ImmunoEdge, retrieved 2026].

ImmunoEdge’s stated edge rests on a technical claim of superior recovery from minimal samples, a focus that addresses a specific clinical bottleneck. The company’s early positioning within the BioRN life-science cluster in Heidelberg provides [PUBLIC] access to a dense network of academic and translational oncology expertise [BioRN, Q1 2026]. This potential talent and collaboration advantage is geographically anchored but perishable if the company cannot translate academic relationships into proprietary IP or commercial partnerships. The core technological edge, as described, is also perishable; it depends on achieving and maintaining a significant sensitivity lead over improvements that incumbents like Illumina or Waters could bake into their next-generation instruments or that competitors could develop in-house.

The company’s most significant exposure is its lack of an integrated therapeutic pipeline. In a segment where companies like Immatics control the entire value chain from discovery to clinic, a tools-only provider like ImmunoEdge is vulnerable to disintermediation. Its success is contingent on convincing those integrated players that its platform offers a uniquely valuable input they cannot efficiently replicate.

A plausible 18-month scenario sees the competitive landscape bifurcating based on validation. If ImmunoEdge can publish a peer-reviewed study or secure a named pharmaceutical collaboration demonstrating its technology’s superiority on real, scarce clinical samples, it becomes an attractive partner or acquisition target for an integrated player like Immatics seeking to bolster its discovery engine. In this scenario, a winner would be a large biopharma partner that gains exclusive access to a high-fidelity target stream. Conversely, if the technical claims remain unproven or if a major platform company (e.g., Illumina through a partnership or acquisition) launches a competing low-input workflow, ImmunoEdge’s narrow wedge could be eroded. The loser in this case would be any standalone tools company that fails to secure a deep, exclusive partnership before the enabling technology becomes a commoditized feature of broader platforms.

Data Accuracy: YELLOW -- Competitive positioning is sourced from company descriptions and public filings; ImmunoEdge's specific technical differentiator is from a single cluster announcement. The competitive analysis includes inferred market structure.

Opportunity

PUBLIC The potential prize for ImmunoEdge is the creation of a foundational data layer for the next wave of personalized cancer immunotherapies, a market projected to reach tens of billions of dollars if it can solve the critical bottleneck of target discovery from real-world patient samples.

The headline opportunity is to become the default immunopeptidomics platform for clinical-stage biopharma. Current workflows for discovering tumor-specific peptides, or neoepitopes, are constrained by sample requirements and sensitivity, often missing the very targets that could drive effective T-cell therapies [ImmunoEdge, retrieved 2026]. ImmunoEdge's stated aim is to unlock these targets from the small, serial biopsies that are a clinical reality in oncology [BioRN, Q1 2026]. If the technology performs as described, it would shift the discovery paradigm from a research tool to a clinical decision-support system, enabling the design of more potent and personalized vaccines and cell therapies. This outcome is reachable because the need is well-documented; the company's entry into the BioRN cluster provides a credible, if early, validation of its technical focus within a recognized European biotech ecosystem [BioRN, Q1 2026].

Growth would likely follow one of several concrete paths, each hinging on a specific catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Platform Partner	ImmunoEdge's technology is licensed or embedded into the R&D workflows of top-20 oncology-focused biopharma companies.	A published, peer-reviewed validation study demonstrating superior peptide recovery from low-input clinical samples versus standard methods.	The industry's reliance on external innovation for target discovery is established; a superior tool with clinical-grade data would attract partnership interest.
Diagnostic Enabler	The company transitions from a discovery service to providing a regulated assay or kit for longitudinal monitoring of immunotherapy patients.	Securing a CE mark or FDA breakthrough device designation for a monitoring application.	The push for real-time, minimally invasive biomarkers to track treatment response is a major trend in immuno-oncology, creating a clear regulatory pathway for such tools.

Compounding success would manifest as a deepening data moat. Each successful partnership or clinical study would generate proprietary datasets linking specific peptide signatures to patient outcomes. This repository of clinically validated targets would not only improve the platform's predictive algorithms but also create a high barrier to entry for competitors. The company's focus on longitudinal monitoring is particularly potent for this flywheel, as repeated sampling from the same patients over time would generate uniquely valuable temporal data on target evolution under therapeutic pressure [ImmunoEdge, retrieved 2026].

The size of the win can be framed by looking at comparable companies that have built valuable businesses on enabling technology. Immatics, a publicly traded company in the same broad space of target discovery for cell therapies, reached a market capitalization of approximately $1.2 billion in early 2025 [public financials, 2025]. While ImmunoEdge is at a far earlier stage, a successful execution of the Platform Partner scenario could position it as a similarly critical, high-margin enabler. In that context, capturing a meaningful share of the immunopeptidomics tools and services market,a segment of the broader multi-billion dollar immuno-oncology R&D spend,could support a valuation in the hundreds of millions of dollars (scenario, not a forecast).

Data Accuracy: YELLOW -- The opportunity analysis is based on the company's stated aims and well-documented industry needs, but specific catalysts and comparables are extrapolated from the broader market context rather than direct company evidence.

Sources

PUBLIC

1. [BioRN, Q1 2026] Introducing our New Members - Q1 2026 | https://biorn.org/introducing-our-new-members-q1-2026/

2. [ImmunoEdge, retrieved 2026] ImmunoEdge | https://www.immunoedge.de

3. [LinkedIn] ImmunoEdge LinkedIn Page | https://www.linkedin.com/company/immunoedge

4. [Precedence Research, 2024] Personalized Cancer Vaccine Market | https://www.precedenceresearch.com/personalized-cancer-vaccine-market

5. [Immatics, 2024] Immatics Corporate Website | https://www.immatics.com

6. [NantWorks, 2024] NantWorks Corporate Website | https://www.nantworks.com

7. [Illumina, 2024] Illumina Corporate Website | https://www.illumina.com

8. [Waters, 2024] Waters Corporate Website | https://www.waters.com

9. [public financials, 2025] Immatics Market Capitalization | https://finance.yahoo.com/quote/IMTX/